Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: The SAKK experience

Wils JA, Klein HO, Wagener DJTh, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin—A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991, 9, 827–831.

Leichman, 1991, Cisplatin therapy for adenocarcinoma of the stomach, Semin Oncol, 18, 25

Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992, 10, 541–548.

Cocconi G, Bella M, Zironi S, et al. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994, 12, 2687–2693.

Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 1989, 7, 1318–1326.

Preusser, 1989, Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric carcinoma, J Clin Oncol, 7, 1310, 10.1200/JCO.1989.7.9.1310

Katz A, Gansl RC, Simon SD, et al. Phase II trial of etoposide (V), adriamycin (A), and cisplatinum (P) in patients with metastatic gastric cancer. Am J Clin Oncol 1991; 14, 357–358.

Lerner, 1992, Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial, J Clin Oncol, 10, 536, 10.1200/JCO.1992.10.4.536

Joss RA, Bacchi M, Hurny C, et al. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1995, 6, 157–166.

Simon, 1989, Optimal two-stage designs for phase II clinical trials, Controlled Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9

Rougier Ph, Wils J, Wilke H, et al. Advanced gastric cancer: comparison of FAMTX (5FU, adriamycin, methotrexate) versus ELF (etoposide, 5-FU, leucovorin) versus FUP (infusional 5-FU+cisplatin). Results from an EORTC trial of the GITCCG and the Arbeitsgemeinschafl für innere Onkologie (AIO). Eur J Cancer 1995, 31A, S116 (Abstract).

Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997, 15, 261–267.

Cascinu S, Labianca R, Alessandroni P, et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997, 15, 3313–3319.

Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group [see comments]. Br J Cancer 1994, 70, 380–383.

Fuchs, 1997, Chemotherapy for advanced gastric cancer: where do we stand?, J Clin Oncol, 15, 3299, 10.1200/JCO.1997.15.11.3299

Roth AD, Maibach R, Martinelli G, et al. Taxotere–cisplatin (TC) in advanced gastric carcinoma (AGC): a promising drug combination. Eur J Cancer 1997, 33(Suppl. 8), S274 (Abstract).